Altering cell death pathways as an approach to cure HIV infection

Cell Death and Disease

Volumn 4, Issue 7, 2013, Pages

  Badley, A D ^a   Sainski, A ^a   Wightman, F ^b,c   Lewin, S R ^b,c  

^a MAYO CLINIC   (United States)

^b ALFRED HOSPITAL   (Australia)

^c BURNET INSTITUTE   (Australia)

Author keywords

Apoptosis; Bcl2; Casp8p41; HIV cure; Latency

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTIRETROVIRUS AGENT; APICIDIN; BELINOSTAT; BRYOSTATIN; BUTYRIC ACID; CHETOCIN; DNA METHYLTRANSFERASE INHIBITOR; ENTINOSTAT; GIVINOSTAT; GROWTH HORMONE; HISTONE DEACETYLASE INHIBITOR; INTERLEUKIN 15; INTERLEUKIN 7; MONOCARBOXYLATE TRANSPORTER 1; N (1 BENZYL 4 PIPERIDINYL) 2 (HEXAHYDRO 4 METHYL 1H 1,4 DIAZEPIN 1 YL) 6,7 DIMETHOXY 4 QUINAZOLINAMINE; OXAMFLATIN; PANOBINOSTAT; PROSTRATIN; PROTEIN KINASE C; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR AGONIST; TRICHOSTATIN A; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VORINOSTAT;

APOPTOSIS; CD4+ T LYMPHOCYTE; CELL DEATH; CYTOTOXICITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LATENT VIRUS INFECTION; NONHUMAN; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; REVIEW;

EID: 84881074003     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2013.248     Document Type: Review

References (139)

1. Allers K, Hutter G, Hofmann J, Loddenkemper C, Rieger K, Thiel E et al. Evidence for the cure of HIV infection by CCR5D32/D32 stem cell transplantation. Blood 2010; 117: 2791-2799.
2. Hutter G, Nowak D, Mossner M, Ganepola S, Mussig A, Allers K et al. Long-term control of HIV by CCR5 D32/D32 stem-cell transplantation. N Engl J Med 2009; 360: 692-698.
3. Hutter G, Thiel E. Allogeneic transplantation of CCR5-deficient progenitor cells in a patient with HIV infection: an update after 3 years and the search for patient no. AIDS 2011; 25: 273-274.
4. Suzuki Y, Nagao Y, Kato H, Matsumoto M, Nerome K, Nakajima K et al. Human influenza A virus hemagglutinin distinguishes sialyloligosaccharides in membrane-associated gangliosides as its receptor which mediates the adsorption and fusion processes of virus infection. Specificity for oligosaccharides and sialic acids and the sequence to which sialic acid is attached. J Biol Chem 1986; 261: 17057-17061.
5. Weis W, Brown JH, Cusack S, Paulson JC, Skehel JJ, Wiley DC. Structure of the influenza virus haemagglutinin complexed with its receptor, sialic acid. Nature 1988; 333: 426-431.
6. Ivan FX, Tan KS, Phoon MC, Engelward BP, Welsch RE, Rajapakse JC et al. Neutrophils infected with highly virulent influenza H3N2 virus exhibit augmented early cell death and rapid induction of type I interferon signaling pathways. Genomics 2012 pii: S0888-7543(12)00228-5.
7. Cho JL, Roche MI, Sandall B, Brass AL, Seed B, Xavier RJ et al. Enhanced Tim3 activity improves survival after influenza infection. J Immunol 2012; 189: 2879-2889.
8. Mukherjee S, Majumdar S, Vipat VC, Mishra AC, Chakrabarti AK. Non structural protein of avian influenza A (H11N1) virus is a weaker suppressor of immune responses but capable of inducing apoptosis in host cells. Virol J 2012; 9: 149.
9. Lam WY, Yeung AC, Chan PK. Apoptosis, cytokine and chemokine induction by nonstructural 1 (NS1) proteins encoded by different influenza subtypes. Virol J 2011; 8: 554.
10. Han X, Li Z, Chen H, Wang H, Mei L, Wu S et al. Influenza virus A/Beijing/501/2009(H1N1) NS1 interacts with beta-tubulin and induces disruption of the microtubule network and apoptosis on A549 cells. PLoS One 2012; 7: e48340.
11. Galluzzi L, Brenner C, Morselli E, Touat Z, Kroemer G. Viral control of mitochondrial apoptosis. PLoS Pathog 2008; 4: e1000018.
12. Altmann M, Hammerschmidt W. Epstein-Barr virus provides a new paradigm: a requirement for the immediate inhibition of apoptosis. PLoS Biol 2005; 3: e404.
13. Lum JJ, Badley AD. Resistance to apoptosis: mechanism for the development of HIV reservoirs. Curr HIV Res 2003; 1: 261-274.
14. Badley AD, Parato K, Cameron DW, Kravcik S, Phenix BN, Ashby D et al. Dynamic correlation of apoptosis and immune activation during treatment of HIV infection. Cell Death Differ 1999; 6: 420-432.
15. Lopez-Huertas MR, Mateos E, Sanchez Del Cojo M, Gomez-Esquer F, Diaz-Gil G, Rodriguez-Mora S et al. The presence of HIV-1 Tat second exon delays Fas-mediated apoptosis in CD4\+ T lymphocytes: a potential mechanism for persistent viral production. J Biol Chem 2013; 288: 7626-7644.
16. Conti L, Rainaldi G, Matarrese P, Varano B, Rivabene R, Columba S et al. The HIV-1 vpr protein acts as a negative regulator of apoptosis in a human lymphoblastoid T cell line: possible implications for the pathogenesis of AIDS. J Exp Med 1998; 187: 403-413.
17. Berro R, de la Fuente C, Klase Z, Kehn K, Parvin L, Pumfery A et al. Identifying the membrane proteome of HIV-1 latently infected cells. J Biol Chem 2007; 282: 8207-8218.
18. Zheng L, Yang Y, Guocai L, Pauza CD, Salvato MS. HIV Tat protein increases Bcl-2 expression in monocytes which inhibits monocyte apoptosis induced by tumor necrosis factor-alpha-related apoptosis-induced ligand. Intervirology 2007; 50: 224-228.
19. Chehimi J, Papasavvas E, Tomescu C, Gekonge B, Abdulhaqq S, Raymond A et al. Inability of plasmacytoid dendritic cells to directly lyse HIV-infected autologous CD4\+ T cells despite induction of tumor necrosis factor-related apoptosis-inducing ligand. J Virol 2010; 84: 2762-2773.
20. Schnepple DJ, Shepard B, Bren GD, Cummins NW, Natesampillai S, Trushin S et al. Isolation of a TRAIL antagonist from the serum of HIV-infected patients. J Biol Chem 2011; 286: 35742-35754.
21. Lopez-Huertas MR, Mateos E, Sanchez Del Cojo M, Gomez-Esquer F, Diaz-Gil G, Rodriguez-Mora S et al. The presence of HIV-1 Tat protein second exon delays Fas protein-mediated apoptosis in CD4\+ T lymphocytes: a potential mechanism for persistent viral production. J Biol Chem 2013; 288: 7626-7644.
22. Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T et al. Latent infection of CD4\+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999; 5: 512-517.
23. Pierson T, McArthur J, Siliciano RF. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. Annu Rev Immunol 2000; 18: 665-708.
24. Chun TW, Nickle DC, Justement JS, Meyers JH, Roby G, Hallahan CW et al. Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy. J Infect Dis 2008; 197: 714-720.
25. Embretson J, Zupancic M, Ribas JL, Burke A, Racz P, Tenner-Racz K et al. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature 1993; 362: 359-362.
26. Wightman F, Solomon A, Khoury G, Green JA, Gray L, Gorry PR et al. Both CD31(\+) and CD31(-) naive CD4(\+) T cells are persistent HIV type 1-infected reservoirs in individuals receiving antiretroviral therapy. J Infect Dis 2010; 202: 1738-1748.
27. Spiegel H, Herbst H, Niedobitek G, Foss HD, Stein H. Follicular dendritic cells are a major reservoir for human immunodeficiency virus type 1 in lymphoid tissues facilitating infection of CD4\+ T-helper cells. Am J Pathol 1992; 140: 15-22.
28. Tornatore C, Chandra R, Berger JR, Major EO. HIV-1 infection of subcortical astrocytes in the pediatric central nervous system. Neurology 1994; 44(3 Pt 1): 481-487.
29. He J, Chen Y, Farzan M, Choe H, Ohagen A, Gartner S et al. CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia. Nature 1997; 385: 645-649.
30. Deeks SG, Autran B, Berkhout B, Benkirane M, Cairns S, Chomont N et al. Towards an HIV cure: a global scientific strategy. Nat Rev Immunol 2012; 12: 607-614.
31. Williams SA, Chen LF, Kwon H, Ruiz-Jarabo CM, Verdin E, Greene WC. NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation. EMBO J 2006; 25: 139-149.
32. Treand C, du Chene I, Bres V, Kiernan R, Benarous R, Benkirane M et al. Requirement for SWI/SNF chromatin-remodeling complex in Tat-mediated activation of the HIV-1 promoter. EMBO J 2006; 25: 1690-1699.
33. Han Y, Lin YB, An W, Xu J, Yang HC, O'Connell K et al. Orientation-dependent regulation of integrated HIV-1 expression by host gene transcriptional readthrough. Cell Host Microbe 2008; 4: 134-146.
34. Pace MJ, Agosto L, Graf EH, O'Doherty U. HIV reservoirs and latency models. Virology 2011; 411: 344-354.
35. Duh EJ, Maury WJ, Folks TM, Fauci AS, Rabson AB. Tumor necrosis factor alpha activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-kappa B sites in the long terminal repeat. Proc Natl Acad Sci USA 1989; 86: 5974-5978.
36. Folks TM, Justement J, Kinter A, Dinarello CA, Fauci AS. Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line. Science 1987; 238: 800-802.
37. Jordan A, Bisgrove D, Verdin E. HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J 2003; 22: 1868-1877.
38. Kutsch O, Benveniste EN, Shaw GM, Levy DN. Direct and quantitative single-cell analysis of human immunodeficiency virus type 1 reactivation from latency. J Virol 2002; 76: 8776-8786.
39. Chun TW, Carruth L, Finzi D, Shen X, DiGiuseppe JA, Taylor H et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997; 387: 183-188.
40. Dokmanovic M, Marks PA. Prospects: histone deacetylase inhibitors. J Cell Biochem 2005; 96: 293-304.
41. Shan L, Yang HC, Rabi SA, Bravo HC, Shroff NS, Irizarry RA et al. Influence of host gene transcription level and orientation on HIV-1 latency in a primary-cell model. J Virol 2011; 85: 5384-5393.
42. Marini A, Harper JM, Romerio F. An in vitro system to model the establishment and reactivation of HIV-1 latency. J Immunol 2008; 181: 7713-7720.
43. Burnett JC, Lim KI, Calafi A, Rossi JJ, Schaffer DV, Arkin AP. Combinatorial latency reactivation for HIV-1 subtypes and variants. J Virol 2010; 84: 5958-5974.
44. Lassen KG, Hebbeler AM, Bhattacharyya D, Lobritz MA, Greene WC. A flexible model of HIV-1 latency permitting evaluation of many primary CD4 T-cell reservoirs. PLoS One 2012; 7: e30176.
45. Cameron PU, Saleh S, Sallmann G, Solomon A, Wightman F, Evans VA et al. Establishment of HIV-1 latency in resting CD4\+ T cells depends on chemokineinduced changes in the actin cytoskeleton. Proc Natl Acad Sci USA 2010; 107: 16934-16939.
46. Saleh S, Solomon A, Wightman F, Xhilaga M, Cameron PU, Lewin SR. CCR7 ligands CCL19 and CCL21 increase permissiveness of resting memory CD4\+ T cells to HIV-1 infection: a novel model of HIV-1 latency. Blood 2007; 110: 4161-4164.
47. Yang HC, Xing S, Shan L, O'Connell K, Dinoso J, Shen A et al. Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation. J Clin Invest 2009; 119: 3473-3486.
48. Archin NM, Espeseth A, Parker D, Cheema M, Hazuda D, Margolis DM. Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res Hum Retroviruses 2009; 25: 207-212.
49. Ya-Chi Ho LS, Wang J, Hosmane N, Blankson J, Siliciano R. Characterization of noninduced HIV-1 proviruses dampens the hope for HIV-1 eradication. 20th Conference on Retroviruses and Opportunistic Infections, Atlanta [abstract 43] 2013.
50. Chinnaiyan AM, Woffendin C, Dixit VM, Nabel GJ. The inhibition of pro-apoptotic ICE-like proteases enhances HIV replication. Nat Med 1997; 3: 333-337.
51. Aillet F, Masutani H, Elbim C, Raoul H, Chene L, Nugeyre MT et al. Human immunodeficiency virus induces a dual regulation of Bcl-2, resulting in persistent infection of CD4(\+) T-or monocytic cell lines. J Virol 1998; 72: 9698-9705.
52. Wang X, Ragupathy V, Zhao J, Hewlett I. Molecules from apoptotic pathways modulate HIV-1 replication in Jurkat cells. Biochem Biophys Res Commun 2011; 414: 20-24.
53. Bren GD, Whitman J, Cummins N, Shepard B, Rizza SA, Trushin SA et al. Infected cell killing by HIV-1 protease promotes NF-kappaB dependent HIV-1 replication. PLoS One 2008; 3: e2112.
54. Weng NP, Araki Y, Subedi K. The molecular basis of the memory T cell response: differential gene expression and its epigenetic regulation. Nat Rev Immunol 2012; 12: 306-315.
55. Cummins NW, Badley A. Mechanisms of HIV-associated lymphocyte apoptosis: 2010. Cell Death Dis 2010; 1: e99.
56. Unsoeld H, Pircher H. Complex memory T-cell phenotypes revealed by coexpression of CD62L and CCR7. J Virol 2005; 79: 4510-4513.
57. Loetscher P, Uguccioni M, Bordoli L, Baggiolini M, Moser B, Chizzolini C et al. CCR5 is characteristic of Th1 lymphocytes. Nature 1998; 391: 344-345.
58. Zaunders JJ, Ip S, Munier ML, Kaufmann DE, Suzuki K, Brereton C et al. Infection of CD127\+ (interleukin-7 receptor\+) CD4\+ cells and overexpression of CTLA-4 are linked to loss of antigen-specific CD4 T cells during primary human immunodeficiency virus type 1 infection. J Virol 2006; 80: 10162-10172.
59. Trushin SA, Carena AA, Bren GD, Rizza SA, Dong X, Abraham RS et al. SDF-1alpha degrades whereas glycoprotein 120 upregulates Bcl-2 interacting mediator of death extralong isoform: implications for the development of T cell memory. J Immunol 2012; 189: 1835-1842.
60. Saez-Cirion A, Bacchus C, Hocqueloux L, Avettand-Fenoel V, Girault I, Lecuroux C et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog 2013; 9: e1003211.
61. Lodi S, Meyer L, Kelleher AD, Rosinska M, Ghosn J, Sannes M et al. Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion. Arch Intern Med 2012; 172: 1252-1255.
62. Persaud D, Gay H, Ziemniak C, Chen YH, Piatak M, Chun T-W et al. Functional HIV cure after very early ART of an infected infant. 20th Conference on Retroviruses and Opportunistic Infections 3-6 March 2013 Atlanta, GA [abstract 48LB].
63. Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, Crooks AM et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 2012; 487: 482-485.
64. Elliott J, Soloman A, Whightman F, Smith M, Palmer S, Prince M et al. The safety and effect of multiple doses of vorinostat on HIV transcription in HIV\+ patients receiving cART. 20th Conference on Retroviruses and Opportunistic Infections Atlanta, GA [abstract 50LB] 2013.
65. Siliciano JD. Safety and feasibility of using disulfiram to enhance HIV transcription among long-term ARV-treated adults: preliminary results from a Pilot study 2012; 1.
66. Shehu-Xhilaga M, Rhodes D, Wightman F, Liu HB, Solomon A, Saleh S et al. The novel histone deacetylase inhibitors metacept-1 and metacept-3 potently increase HIV-1 transcription in latently infected cells. AIDS 2009; 23: 2047-2050.
67. Shan L, Deng K, Shroff NS, Durand CM, Rabi SA, Yang HC et al. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 2012; 36: 491-501.
68. Bosque A, Famiglietti M, Weyrich AS, Goulston C, Planelles V. Homeostatic proliferation fails to efficiently reactivate HIV-1 latently infected central memory CD4\+ T cells. PLoS Pathog 2011; 7: e1002288.
69. Perez EE, Wang J, Miller JC, Jouvenot Y, Kim KA, Liu O et al. Establishment of HIV-1 resistance in CD4\+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol 2008; 26: 808-816.
70. Yuan J, Wang J, Crain K, Fearns C, Kim KA, Hua KL et al. Zinc-finger nuclease editing of human cxcr4 promotes HIV-1 CD4(\+) T cell resistance and enrichment. Mol Ther 2012; 20: 849-859.
71. Lai Y. CCR5-targeted hematopoietic stem cell gene approaches for HIV disease: current progress and future prospects. Curr Stem Cell Res Ther 2012; 7: 310-317.
72. Stremlau M, Perron M, Welikala S, Sodroski J. Species-specific variation in the B30.2(SPRY) domain of TRIM5alpha determines the potency of human immunodeficiency virus restriction. J Virol 2005; 79: 3139-3145.
73. Balazs AB, Chen J, Hong CM, Rao DS, Yang L, Baltimore D. Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature 2012; 481: 81-84.
74. Veselinovic M, Neff CP, Mulder LR, Akkina R. Topical gel formulation of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 confers protection against HIV-1 vaginal challenge in a humanized mouse model. Virology 2012; 432: 505-510.
75. Sadelain M, Brentjens R, Riviere I. The promise and potential pitfalls of chimeric antigen receptors. Curr Opin Immunol 2009; 21: 215-223.
76. Brentjens RJ, Riviere I, Park JH, Davila ML, Wang X, Stefanski J et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 2011; 118: 4817-4828.
77. Scholler J, Brady TL, Binder-Scholl G, Hwang WT, Plesa G, Hege KM et al. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med 2012; 4: 132ra53.
78. Li MJ, Kim J, Li S, Zaia J, Yee JK, Anderson J et al. Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolar-localizing TAR decoy. Mol Ther 2005; 12: 900-909.
79. DiGiusto DL, Krishnan A, Li L, Li H, Li S, Rao A et al. RNA-based gene therapy for HIV with lentiviral vector-modified CD34(\+) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci Transl Med 2010; 2: 36ra43.
80. Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, Allikmets R et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 1996; 273: 1856-1862.
81. Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996; 86: 367-377.
82. Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber CM et al. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996; 382: 722-725.
83. Pereyra F, Jia X, McLaren PJ, Telenti A, de Bakker PI,Walker BD et al. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 2010; 330: 1551-1557.
84. Martin MP, Qi Y, Gao X, Yamada E, Martin JN, Pereyra F et al. Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat Genet 2007; 39: 733-740.
85. Migueles SA, Osborne CM, Royce C, Compton AA, Joshi RP, Weeks KA et al. Lytic granule loading of CD8\+ T cells is required for HIV-infected cell elimination associated with immune control. Immunity 2008; 29: 1009-1021.
86. Rajasuriar R, Khoury G, Kamarulzaman A, French MA, Cameron PU, Lewin SR. Persistent immune activation in chronic HIV infection: do any interventions work? AIDS 2013.
87. Hatano H, Jain V, Hunt PW, Lee TH, Sinclair E, Do TD et al. Cell-based measures of viral persistence are associated with immune activation and programmed cell death protein 1 (PD-1)-expressing CD4\+ T cells. J Infect Dis 2012; 208: 50-56.
88. Taiwo B, Hunt PW, Gandhi RT, Ellingson A, McKenna M, Jacobson JM et al. CD8\+ T-cell activation in HIV-1-infected patients experiencing transient low-level viremia during antiretroviral therapy. J Acquir Immune Defic Syndr 2013; 63: 101-104.
89. Gandhi RT, Zheng L, Bosch RJ, Chan ES, Margolis DM, Read S et al. on behalf of the ACTGAt. The effect of Raltegravir intensification on low-level residual viremia in HIVinfected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med 2010; 7: e1000321.
90. Hiroyu Hatano MS, Scherzer R, Sinclair E, Palmer S, Busch M, Bacchetti P et al. Increase in 2-LTR circles after raltegravir intensification in HAART-suppressed patients with high CD4\+ T cell counts: a randomized, controlled trial. 20th Conference on Retroviruses and Opportunistic Infections, 3-6 March 2013, Atlanta GA (Abstract 42).
91. Chun TW, Davey RT Jr., Engel D, Lane HC, Fauci AS. Re-emergence of HIV after stopping therapy. Nature 1999; 401: 874-875.
92. Levy Y, Lacabaratz C, Weiss L, Viard JP, Goujard C, Lelievre JD et al. Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment. J Clin Invest 2009; 119: 997-1007.
93. Sereti I, Dunham RM, Spritzler J, Aga E, Proschan MA, Medvik K et al. IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection. Blood 2009; 113: 6304-6314.
94. Levy Y, Sereti I, Tambussi G, Routy JP, Lelievre JD, Delfraissy JF et al. Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy: results of a phase I/IIa randomized, placebocontrolled, multicenter study. Clin Infect Dis 2012; 55: 291-300.
95. Seder RA, Grabstein KH, Berzofsky JA, McDyer JF. Cytokine interactions in human immunodeficiency virus-infected individuals: roles of interleukin (IL)-2, IL-12, and IL-15. J Exp Med 1995; 182: 1067-1077.
96. Lum JJ, Schnepple DJ, Nie Z, Sanchez-Dardon J, Mbisa GL, Mihowich J et al. Differential effects of interleukin-7 and interleukin-15 on NK cell anti-human immunodeficiency virus activity. J Virol 2004; 78: 6033-6042.
97. Mueller YM, Do DH, Altork SR, Artlett CM, Gracely EJ, Katsetos CD et al. IL-15 treatment during acute simian immunodeficiency virus (SIV) infection increases viral set point and accelerates disease progression despite the induction of stronger SIV-specific CD8\+ T cell responses. J Immunol 2008; 180: 350-360.
98. Pallikkuth S, Parmigiani A, Pahwa S. Role of IL-21 and IL-21 receptor on B cells in HIV infection. Crit Rev Immunol 2012; 32: 173-195.
99. Pallikkuth S, Rogers K, Villinger F, Dosterii M, Vaccari M, Franchini G et al. Interleukin-21 administration to rhesus macaques chronically infected with simian immunodeficiency virus increases cytotoxic effector molecules in T cells and NK cells and enhances B cell function without increasing immune activation or viral replication. Vaccine 2011; 29: 9229-9238.
100. Conti L, Matarrese P, Varano B, Gauzzi MC, Sato A, Malorni W et al. Dual role of the HIV-1 vpr protein in the modulation of the apoptotic response of T cells. J Immunol 2000; 165: 3293-3300.
101. Fernandez Larrosa PN, Croci DO, Riva DA, Bibini M, Luzzi R, Saracco M et al. Apoptosis resistance in HIV-1 persistently-infected cells is independent of active viral replication and involves modulation of the apoptotic mitochondrial pathway. Retrovirology 2008; 5: 19.
102. Azmi AS, Wang Z, Philip PA, Mohammad RM, Sarkar FH. Emerging Bcl-2 inhibitors for the treatment of cancer. Expert Opin Emerg Drugs 2011; 16: 59-70.
103. Gyrd-Hansen M, Meier P. IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer. Nat Rev Cancer 2010; 10: 561-574.
104. Reddy N, Czuczman MS. Enhancing activity and overcoming chemoresistance in hematologic malignancies with bortezomib: preclinical mechanistic studies. Ann Oncol 2010; 21: 1756-1764.
105. Mita AC, Mita MM, Nawrocki ST, Giles FJ. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res 2008; 14: 5000-5005.
106. Kim D, Cheng GZ, Lindsley CW, Yang H, Cheng JQ. Targeting the phosphatidylinositol-3 kinase/Akt pathway for the treatment of cancer. Curr Opin Investig Drugs 2005; 6: 1250-1258.
107. Sayers TJ. Targeting the extrinsic apoptosis signaling pathway for cancer therapy. Cancer Immunol Immunother 2011; 60: 1173-1180.
108. Nie Z, Bren GD, Vlahakis SR, Schimnich AA, Brenchley JM, Trushin SA et al. Human immunodeficiency virus type 1 protease cleaves procaspase 8 in vivo. J Virol 2007; 81: 6947-6956.
109. Strauss G, Knape I, Melzner I, Debatin KM. Constitutive caspase activation and impaired death-inducing signaling complex formation in CD95-resistant, long-term activated, antigen-specific T cells. J Immunol 2003; 171: 1172-1182.
110. Li X, Jiang S, Tapping RI. Toll-like receptor signaling in cell proliferation and survival. Cytokine 2010; 49: 1-9.
111. Caron G, Duluc D, Fremaux I, Jeannin P, David C, Gascan H et al. Direct stimulation of human T cells via TLR5 and TLR7/8: flagellin and R-848 up-regulate proliferation and IFN-gamma production by memory CD4\+ T cells. J Immunol 2005; 175: 1551-1557.
112. Thibault S, Imbeault M, Tardif MR, Tremblay MJ. TLR5 stimulation is sufficient to trigger reactivation of latent HIV-1 provirus in T lymphoid cells and activate virus gene expression in central memory CD4\+ T cells. Virology 2009; 389: 20-25.
113. Montefiori DC, Mitchell WM. Antiviral activity of mismatched double-stranded RNA against human immunodeficiency virus in vitro. Proc Natl Acad Sci USA 1987; 84: 2985-2989.
114. Guidi F, Puglia M, Gabbiani C, Landini I, Gamberi T, Fregona D et al. 2D-DIGE analysis of ovarian cancer cell responses to cytotoxic gold compounds. Mol Biosyst 2012; 8: 985-993.
115. Lewis MG, DaFonseca S, Chomont N, Palamara AT, Tardugno M, Mai A et al. Gold drug auranofin restricts the viral reservoir in the monkey AIDS model and induces containment of viral load following ART suspension. AIDS 2011; 25: 1347-1356.
116. Huber K, Doyon G, Plaks J, Fyne E, Mellors JW, Sluis-Cremer N. Inhibitors of histone deacetylases: correlation between isoform specificity and reactivation of HIV type 1 (HIV-1) from latently infected cells. J Biol Chem 2011; 286: 22211-22218.
117. Reuse S, Calao M, Kabeya K, Guiguen A, Gatot JS, Quivy V. Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection. PLoS One 2009; 4: e6093.
118. Savarino A, Mai A, Norelli S, El Daker S, Valente S, Rotili D et al. "Shock and kill" effects of class I-selective histone deacetylase inhibitors in combination with the glutathione synthesis inhibitor buthionine sulfoximine in cell line models for HIV-1 quiescence. Retrovirology 2009; 6: 52.
119. Choi BS, Lee HS, Oh YT, Hyun YL, Ro S, Kim SS et al. Novel histone deacetylase inhibitors CG05 and CG06 effectively reactivate latently infected HIV-1. AIDS 2010; 24: 609-611.
120. Archin NM, Keedy KS, Espeseth A, Dang H, Hazuda DJ, Margolis DM. Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors. AIDS 2009; 23: 1799-1806.
121. Matalon S, Palmer BE, Nold MF, Furlan A, Kassu A, Fossati G et al. The histone deacetylase inhibitor ITF2357 decreases surface CXCR4 and CCR5 expression on CD4(\+) T-cells and monocytes and is superior to valproic acid for latent HIV-1 expression in vitro. J Acquir Immune Defic Syndr 2010; 54: 1-9.
122. Victoriano AF, Imai K, Togami H, Ueno T, Asamitsu K, Suzuki T et al. Novel histone deacetylase inhibitor NCH-51 activates latent HIV-1 gene expression. FEBS Lett 2011; 585: 1103-1111.
123. Rasmussen TA, Schmeltz Sogaard O, Brinkmann C, Wightman F, Lewin S, Melchjorsen J et al. Comparison of HDAC inhibitors in clinical development: Effect on HIV production in latently infected cells and T-cell activation. Hum Vaccin Immunother 2013; 9: 5.
124. Wightman F RS, Saleh S et al. Potency and toxicity of HDACi and other immune activators in inducing HIV production using a primary resting T-cell model of HIV latency [abstract 198]. Poster presented at the 18th Conference on Retroviruses and Opportunistic Infections; 27 February-2 March 2011 Boston, MA.
125. Ying H, Zhang Y, Zhou X, Qu X, Wang P, Liu S et al. Selective histonedeacetylase inhibitor M344 intervenes in HIV-1 latency through increasing histone acetylation and activation of NF-kappaB. PLoS One 2012; 7: e48832.
126. Fernandez G, Zeichner SL. Cell line-dependent variability in HIV activation employing DNMT inhibitors. Virol J 2010; 7: 266.
127. Bouchat S, Gatot JS, Kabeya K, Cardona C, Colin L, Herbein G et al. Histone methyltransferase inhibitors induce HIV-1 recovery in resting CD4\+ T cells from HIV-1\+ HAART-treated patients. AIDS 2012; 26: 1473-1482.
128. Bernhard W, Barreto K, Saunders A, Dahabieh MS, Johnson P, Sadowski I. The Suv39H1 methyltransferase inhibitor chaetocin causes induction of integrated HIV-1 without producing a T cell response. FEBS Lett 2011; 585: 3549-3554.
129. Wei G CV, Fyne E, Balakrishnan M, Stepan G, Tsai A et al. Histone deacetylase inhibitor romidepsin induces HIV in CD4\+ T cells from ART-suppressed subjects at concentrations achieved by clinical dosing. 201th Conference on Retroviruses and Opportunistic Infections, Atlanta 2013.
130. Saleh S, Wightman F, Ramanayake S, Alexander M, Kumar N, Khoury G et al. Expression and reactivation of HIV in a chemokine induced model of HIV latency in primary resting CD4\+ T cells. Retrovirology 2011; 8: 80.
131. Perez M, de Vinuesa AG, Sanchez-Duffhues G, Marquez N, Bellido ML, Munoz-Fernandez MA et al. Bryostatin-1 synergizes with histone deacetylase inhibitors to reactivate HIV-1 from latency. Curr HIV Res 2010; 8: 418-429.
132. Klichko V, Archin N, Kaur R, Lehrman G, Margolis D. Hexamethylbisacetamide remodels the human immunodeficiency virus type 1 (HIV-1) promoter and induces Tat-independent HIV-1 expression but blunts cell activation. J Virol 2006; 80: 4570-4579.
133. Shishido T, Wolschendorf F, Duverger A, Wagner F, Kappes J, Jones J et al. Selected drugs with reported secondary cell-differentiating capacity prime latent HIV-1 infection for reactivation. J Virol 2012; 86: 9055-9069.
134. Xing S, Bullen CK, Shroff NS, Shan L, Yang HC, Manucci JL et al. Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4\+ T cell model without inducing global T cell activation. J Virol 2011; 85: 6060-6064.
135. Banerjee C, Archin N, Michaels D, Belkina AC, Denis GV, Bradner J et al. BET bromodomain inhibition as a novel strategy for reactivation of HIV-1. J Leukoc Biol 2012; 92: 1147-1154.
136. Wang FX, Xu Y, Sullivan J, Souder E, Argyris EG, Acheampong EA et al. IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART. J Clin Invest 2005; 115: 128-137.
137. Vandergeeten C, Fonseca SD, Sereti I, Lederman M, Sekaly R-P, Chomont N. Differential impact of IL-7 and IL-15 on HIV reservoir persistence. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 17-20 July, Rome, 2011.
138. DaFonseca S, Chomont N, Far ME, Baulassel R, Routy J, Sekaly R. Purging the HIV-1 reservoir through the disruption of the PD-1 pathway. J Int AIDS Soc 2010 XVII International AIDS Conference, Vienna, Austria.
139. Micheva-Viteva S, Kobayashi Y, Edelstein LC, Pacchia AL, Lee HL, Graci JD et al. High-throughput screening uncovers a compound that activates latent HIV-1 and acts cooperatively with a histone deacetylase (HDAC) inhibitor. J Biol Chem 2011; 286: 21083-21091.